R&D costs on the financial statements: ASC 730 vs. the tax rules

The Section 174 saga of 2022–2024 never touched the income statement's R&D line. ASC 730 has required research and development costs to be expensed as incurred since 1974, and it kept requiring it while the tax law capitalized the same costs over five and fifteen years. The whole episode lived in the tax accounts: a growing deferred tax asset, a cash-tax line running ahead of book tax expense, and — since the OBBBA — the unwinding of both. For finance teams, Section 174A is less a rule change than a large, predictable reversal to model and disclose.

The temporary difference, built and reversed

During 2022–2024, a company with $10 million of annual domestic R&D expensed $10 million for book but deducted only $1 million in year one for tax (five-year amortization, half-year convention). The $9 million excess of book expense over tax deduction was a deductible temporary difference under ASC 740: a deferred tax asset of about $1.9 million at 21%, growing each year the spending continued. Cash taxes exceeded book tax expense by the same measure — the "cash-tax shock" described in the Section 174 pillar — while the effective rate barely moved, since timing differences do not touch it. The pain was visible in the cash flow statement and the DTA rollforward, not the P&L.

Section 174A runs the film backward. New domestic costs deduct currently — no new difference builds. Legacy balances released through the one- or two-year catch-up reverse the accumulated DTA: tax deductions with no corresponding book expense, cash taxes below book tax expense, DTA drawn down to zero. Foreign research remains an exception in both directions — its 15-year tax schedule keeps generating a (smaller) temporary difference indefinitely.

Two book-side wrinkles complicate the symmetry. First, book is not uniformly "expense everything": internal-use software under ASC 350-40 and post-technological-feasibility costs under ASC 985-20 are capitalized for book, so those items can run the opposite direction. Second, the tax SRE pool includes allocable overhead the book R&D line never held — the book-to-tax reconciliation described in identifying SRE expenditures is the workpaper that keeps the DTA computation honest.

ASC 740 in the enactment and transition periods

The OBBBA's effects belonged to the period including July 4, 2025 — ASC 740 records new legislation at enactment, not effectiveness. The main workstreams, most now in their second year:

• Reversal scheduling. The catch-up election (one year versus two) changes when the DTA reverses; the choice is a tax election with a direct financial-statement scheduling consequence.
• Valuation allowances. Loss companies that had written the 174 DTA down reassessed. For small businesses, the retroactive amendment path converts part of the DTA into a current refund receivable — realizable regardless of future income, which can support allowance release. Conversely, a one-year catch-up that merely enlarges an NOL may leave the allowance in place; the amend-or-catch-up economics are in amended return vs. catch-up.
• Interim reporting. The catch-up is a discrete-period or estimated-annual-effective-rate question depending on how elections are made — coordinate the tax provision with the method-change filings described in Section 481(a) and Section 174.
• Disclosure. Users watch the cash-tax benefit: MD&A discussion of the 2025–2026 refund and reduced-payment effects has been standard.